BNGO - Earnings call transcript Q4 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, and welcome to the Bionano Genomics Fourth Quarter and Full Year 2021 Earnings Conference Call. Today’s conference is being recorded. At this time, I would like to turn the conference over to Amy Conrad from Investor Relations. Please go ahead.

Amy Conrad

Thank you, Gigi, and good afternoon, everyone. Genomics call. and Bionano financial year the conference results to fourth full quarter XXXX Welcome call is the Leading today Dr. Erik Holmlin, CEO of Bionano. He of Bionano; Head Chris Stewart, Shippy, by of and Sales of is CBO Global and joined Rich Bionano. CFO After announcing financial release and year results a quarter its XXXX. fourth market today, the closed issued full press Bionano for A Relations company’s the page the website. can found be release of of copy on Investor the anticipated certain Bionano’s the statements advantages forward-looking, I and made in this driving of and would everyone like of XXXX, pipeline, expectations are about current to anticipated recent these conference the improvements system over Saphyr adoption acquisitions, Saphyr sales technologies, and the regarding including plans, that timing for of statements benefits or to strategic the remind commercialization call milestones benefits content of benefits system, of during studies anticipated anticipated and system. the goals Saphyr results, study could upon realized. Such assurances based be forward-looking results statements will that are and current be in statements the no contemplated these there expectations, may differ materially and filed to factors the reports of which and results some release statements such SEC. of press number identified risks, a are with due Bionano’s in from Bionano’s Actual available to assumes forward-looking are on as today, based These obligation and the statements company to change. Bionano information no circumstances statements update

has is by non-GAAP prepared or to isolation prepared in set no GAAP is In measure with in should principles, under is financial read of conjunction statements any the company’s GAAP, with will comparable company’s turn today, to be available expense. company’s An in financial webcast not accounting earnings Investors principles. and standardized results operating end call issued GAAP operating to the to supplement comprehensive the accepted the earlier company consolidated also the or and has This be Bionano’s measures, non-GAAP for IR U.S. financial the audio as will with included company’s today’s GAAP conference addition, of that, the of and posted be operating release over of substitute meaning prescribed call on at accounting a the of been online are expense reported page in non-GAAP Erik. description accordance not I in which expense generally accordance of reconciliation website. GAAP recording or considered website. reporting A With meant operating replay rules the for non-GAAP section

Erik Holmlin

and genome XXXX growth cytogenetics Bionano. XX, a by today. strong. XXX, Thank notable the States, you, saying start out being in optical installed to of across United which Commercially, Amy, Saphyr for Europe, was of systems the afternoon, want and XXXX the laboratories represents over us installed mapping and XX% the results world spectacular I base XX% everyone, several year were with China, the simply December Japan. exceeded our base our XXX thanks nearly and Taiwan medical and to at joining good grew very adopted by academic for goal that on We in Australia, centers

the in flow fourth that And cells which growth same XX% during brings XXXX. the quarter over XXXX over represents flow represents also We the growth period flow sold sold. of for cells total sold X,XXX XX,XXX to the X,XXX in XXXX, XXXX and XX% cells

genome analyzing more leads the more indicate for more which these market the Now to are mapping. purchased consumable flow nanochannel in demand one of flow genome. that unit in we is utilization in cells cell please more more our that presentations data, and for turn publications, The remember the believe human the more arrays optical field, in

$XX for quarter our the $X.X revenues represents XX% XXXX the same up period XXX% XXXX. in the versus XXXX. compared And So were of this in were to fourth is And growth which is XXXX million, million, full revenues progress. year outstanding which

in Now and and positive their an reliably, consistently readout of and while reproducibly interim our genome published The operators. technical optical better that Enrollment progress. tremendous postnatal sample enrollment and these Bionano studies, aberrations genome the approval when sites, received these robustness be showed used also multiple of results of sites performance conducting made more view for and across the in strategy IRB traditional well sites. can I’ll The of laboratories, our as genome mapping be study performing about say mapping will data showed gave also a the methods XXXX interim variations. in and optical XXXX for I postnatal incredibly significant prenatal the than year data reached the optical cover types The XXX utility and reached multiple we the analysis XXX across structural clinical and subjects. in subjects, or mapping different study that goal. is development multiple for performed progress cytogenetics study. And study that chromosomal

menu receiving in Now Saphyr QX the sites accreditation accreditations XXXX. reported potential their OGM reimbursement. and unlock beginning workflows expansion for these for And in Europe

XXX laboratories, year And number quarter XXXX, total we Bionano analyzed same in samples, XXXX. can the was are samples in own analyzed in the get for samples. the submitted enable performed. they quarter analysis were for to they them fourth in PLA in analyzed proprietary of codes, XXXX, applications samples tests, what to tests for paid X,XXX during several While reimbursement the our OGM U.S., compares of in or The including compare and and XXX that during Z XXXX the laboratory that laboratory-developed sites validated that to XXXX. you OGM that XXX codes. These And codes and codes

disease that as we good convince critical their genome optical In these which own currently the including believe to represent we supports to novel genome the ammunition working and principle demand them mapping mapping genome optical We significant when these equity being had to sequencing Version enabling assays developed our disease higher NxClinical software applications the it can Saphyr system provide assays strengthened cancer We many was which ones X.X tremendous and expanded sheet for areas. importantly, analysis given of This and a in capabilities cultured for in their genome for quarter are in indicator the progress samples to we and development, continue enable as of customer then, in And and with well quarter, in-house. and evaluate optical view And in the their first well. of other throughputs chorionic we growth which substantially results. were genetic XXXX, ability balance prenatal version we the services as genome BioDiscovery. they different of mapping. at of bring we applications, improve quarter analysis in for by institutions enable services for the analysis financings released achieving has than quarter, third mapping in optical data the they need aspects released Saphyr with of in And leading proof fourth fourth mapping see these growing Now completed as is next-generation important map in analysis. these optical but we highly prototype are they processed, genome that as product-of-conception expected The to supports optical instrument villi it samples, version company’s new steps, samples. newcomers X.X that with on. genome area prenatal enable our with the the today’s in studies amniocytes workflow. outstanding applications next the important and should environment, optical financially, of provide projects mapping of research product

want XXXX. team brings the we as as for their of reporting And engineers, sequencing including Dr. I this in in move well software took an in microarray to software which BioDiscovery development, products of Lastly, acquisition we interpretation data corporate world-class that important October completed mention of visualization, their step and in of was

Soheil this sorts genome Shams, data. to bioinformatics. for including the reporting genome and but Dr. software analysis. genome of and tool were Founder and valuable for mapping who and focused CEO unique We leads of optical importance of interpretation Informatics the as motivated development our all by informatics software Shams type mapping on a accelerate our has development genome own it’s of our looking And visualization and team, become Officer. optical their Chief accelerating was

incorporate so can these mapping acquiring for these which variation. And gave data And NxClinical a BioDiscovery used the commonly industry. industry-leading is mapping into, optical us alongside the we genome and it us the optical types tool team analyzing genome in platform structural that integrates in gives quickly. applications

the company really the across finances of year, what a our when as our we conclude in products our goals whole strategy, and so really year exceeded that look milestones plan the we we also is back we feel we but advanced And ways the that expectations for all over exceeded planned and across whole, overall.

genome. being from services that’s potential now the transformation suite have people sciences instrumentation a the genomics complete fact, products with global company, on began, company In world into we of that the of XXXX as a all we way elevating a and to focused sees Bionano a view wellness health of where and life transform the the

provide we’ve as improve across I’m momentum time the focusing We product to industry, inflection the and on page on which the representing want to XXXX, We the the we I’d commercially. we We key see there, and us. the change for elevate and very way a that to of to that XXXX accepted. XXXX they’re the built turn proud XXXX. in but want begin So of services company like want

has pillars. the strategic ELEVATE! we fact, called map In strategic for ELEVATE! five-major XXXX, And road

products. customers we validation delight we’ve our genome foremost, in traction and want progress made our the our amazing We and optical to mapping. with want expanding commercial First to continue of that

the our markets, Bionano that summarize about a And software industrial becomes enables something a ELEVATE!. solutions. size want to and target our a for optical make basis. you or to products I’ve path genome installed milestones reimbursement way critical got some is our We that and want new robustness we well to markets mapping at incredibly XXXX to clear as penetration we advancing the for driver market expansion We to need use level connection for and products access on in across want with of strategic of that global of continue in scale. the recognize base applications market and as the into

turn Stewart, you I Chris walk over overview want of CFO, though, our to financials. to that through doing our to an the for Before him call Chris?

Chris Stewart

This from and The an quarter XXXX largely includes of quarter-on-quarter of increases since line moves and with a acquisition achieved to year approximately quarter date. of able the a the of commercial-grade January million of write-off down BioDiscovery Full leverage strong for year off and fourth $X.X the the fourth during from Saphyr margins. write-off and gross fourth over million talking addition quarter of representing margin our chips was mapping The growth, XXXX. of at revenue control I passed grow a XX% categories XX solutions of product revenue the the the of in for at over resulting balance BioDiscovery. slightly contract fourth fell October the our of sheet turnover for this quarter specifications personnel our fourth final minute disappointing an low P&L. begin which was million the business wafers is We specifications, quality In Revenue ship Largely due want to in the across the quarter Revenue I’ll were growth us, million through The XXXX the a or and BioDiscovery. was Gross course, yield $X.X million, one low in we was in $XX XX%, million to in of strategic XX% quality foundry, quarter of driven not on service demand $X.X inventory of to primarily increase COVID chip we high decrease our we’re Erik. key customers. XXXX like fourth yields outstanding review from other XX% year. good to consumables great year-on-year manufacturers BioDiscovery spend of million inventory. failed to of now our XXXX. range by inventory These to produced XX% at at excess and to where continued acquisition year-over-year the our above the meet a year. led optical end year back $X.X manufacturing capped of the XXXX QX, and on geographies. genome quarter of quarter. third margin XXXX. Thanks, XXXX a and, full because a increase X% yields of the compared of and third and about included The XXXX. provided in Revenue for would therefore, supplier, about from million, our $X.X revenues. in all XXX% saw is we’ve but quarter commercial to the revenue gross preliminary of that of $X.X impressive balance disruptions prior $X.X manufacturing came was

quarters actively our may We yields are but issue, they back recover This margin have gross levels. take working get historically to prior for to is with transient a to been. supplier few where it to a

amortization non-GAAP a both useful with prior as our that The are to of million these expense XXXX. non-GAAP million year transaction operating GAAP had first as short-term $X.X headcount-related was in to expense completed and XX, expenses intangibles onetime equity quarter of Bionano both expenses, cash Fourth quarter measure The believe the was compensation, At acquisition for excludes was million. Regarding and way and ongoing compensation, BioDiscovery primarily increased million $X.X expenses well cash primarily million with year-over-year certain our expenses, in of $XX fourth the in investments transaction of $X.X compared our of operating associated $XX.X the noncash expense, expense and transaction-related cash XXXX. million equivalents Non-GAAP acquisition stock-based and as XXXX, $X.X million was year. increase amortization The to performance. additional $X.X Non-GAAP was expense well this million compared other $XX.X noncash XXXX. at intangibles December BioDiscovery. Full expense million, report December operating we $XXX.X quarter, in increase spending, will to providing as we’re the GAAP expense excludes expense. provide more were $XX.X equivalents quarter million due million expense stock-based to in of the XXXX of the we operating quarter of intangibles in costs million in costs. non-GAAP Fourth amortization of XX, R&D costs. in updating and million resulted operating stock-based and that operating million of These our and is cash, year include due expense compared $X.X numbers. of $XX.X XXXX operating raises in $XX operating and GAAP compensation excluding $XX.X

As we’re we strongest begin our XXXX, in position yet.

million, be We quarter. expect to the the in normal of representing fourth QX range $X.X XXXX million declines prior revenue to seasonal from $X.X

questions. and to take We expect million, $XX $XX your before would that, over the I’m call and headed. really growth upcoming we range to Erik about million be be we’ve And our full the to year to revenue XXXX. a the pleased year XX% of turn what in we’re to milestones discuss XX% achieved where ELEVATE! which I’ll over back full with

Erik Holmlin

say Chris. Great. ahead. excited more couldn’t about Thank be the And that you, I really year want we to

challenges for on impact COVID and cautious of our to quality we the progressing the environment our COVID production approval clinical current and progress make focused those IRB first we we the here and believe trials. XXXX. ELEVATE! global beyond going in making chain hematologic are are to be and on In Nevertheless, And studies, supply other remain value-driving events. address, given We getting the half, can milestones concerns. key progress study areas in in of we’re about significant have through clinical macro

for tests; through be study. we’re of second laboratory-developed genome study. market genome addressing to going code be in optical prenatal adding interim on mapping-based completion optical to to half, CPT through continue additional postnatal going also In would tests studies our applications progression be mapping. a our access are to the will for these We have laboratories, an expect Bionano publication We our

and effect accelerating, will releasing of DNA the labeling have isolation the simplifying that OGM by protocols advance We product workflow. also new the will and streamlining protocols

what for imaging optical mapping. version pre-commercial the be of We a in That’s this running will have new going calling high-throughput system field. we’re to genome

around to transitioning systems achieve system the pre-commercial from prototype this in be to the base the is we closing, we installed we systems XXX over XXXX In installed is XXX And the reiterate world from course So terms of of that are finished very the and which Saphyr that expect XXXX what I to increase with. of an want proud achieved. year. we growth we’ll what

offering and just that, critical believe mapping genome But driving transformational And increasing software tool. about mapping, optical optical forward towards Bionano excited solutions to that XXXX. the are of genome to interest recognize a going mainstream optical make see in is and we our mapping, us. in And analytical in really We consistent extremely we that’s now with expanding the a for be adoption genome role genomics. objective adoption beyond we plays that’s across what

our look course, we soon operator, of With that, questions. to so of And we throughout you year. forward take progress to are updating the quarter, quarter and the XXXX, first this about ready

Operator

[Operator Instructions] Sung of from Our the first question BTIG. Ji line comes Nam from

is now line Your open.

Sung Ji Nam

might but for could congratulations do comment, and and for terms in your whether are same from margins the contract taking you questions options talk use able I on you might out and if the with about to And be there alternative platform? the a – – know year. the expect don’t supplier gross next-generation thanks Hi, quarter Starting you issues, supplier to you manufacturing standpoint? the the

Chris Stewart

we’re something possible we’re changes, looking it not changes working chain, this specific it that specific at but and supply robust but looking we’ll always at making as our on point always make, talking is at it. any about is looking as at, Well, something we’re

Sung Ji Nam

is integration OGM – of guys BioDiscovery believe And you. sort to of the year be what Or as some in some the you interim the mentioned that kind of integration into acquisition, I I are had Got software I or there then that this sometime happening the development curious offering sometime going OGM Am Okay. terms year. updates as this correctly? did missing just there. hear far

Erik Holmlin

have on apologize, the of milestone a OGM. half I mentioned that should be NxClinical I release will – that’s second featuring the key the for

part. omission So an my that on was

Sung Ji Nam

Got for lastly then me... worries. No you. And

Erik Holmlin

half. Second

Sung Ji Nam

you then a you think for forward terms terms quarter That Okay. guidance Yes. could in [indiscernible] year? the sense. expectations Chris, makes good fourth Do the the of again, us point in for OpEx it’s in kind spending is give starting kind year? full of the of of your for And spending looking

Chris Stewart

Yes. And non-GAAP again we yes, QX won’t be in of headcount did it think the that is hiring are in starting-off XXXX. But point. – yes, magnitude perspective, a add from continuing so And to of a the strategic areas we we the certainly organization. good

start and the with we year, be if right modest growth ballpark. So QX the throughout in you’d

Sung Ji Nam

much. Okay. you. you so Got Thank

Chris Stewart

you. Thank

Operator

you. Thank

comes of next Our line Cohen Thalmann. from question from the Jeffrey Ladenburg

Your line open. is now

Destiny Buch

for This actually questions. Thank system. I’d some LDTs these new everyone. of for next-generation on and Destiny rollout is Hi, you the like with your of my to Jeff. pre-commercial start taking

XX could LDTs, largest approach what should pre-commercial think how – that about we then Are with think For what How to to we rollout, the would of include? plan or we with you starting your in you of your that? should Some terms that? accounts? five about do accounts? what And

Erik Holmlin

to optical us, are will as for they But will insurance are we with genome think And on I don’t leukemias. continue include optical completely but malignancies. we’re engage and these the payers will them others on for of to but it’s assays. importantly, to it genetic of that the genetic kind we one locked assays. have demand down initial diseases they’ll And LDTs products both These the expand we use heme emphasize And to role revenue side. hematologic be focused to regard leverage the mapping-based to for menu FSHD With strategic drivers reimburse and diseases important of developing. third-party companies the LDTs, be that not such will application, the genome-mapping

gives pre-commercial regard commercial to sites and implement transition to pre-commercial that development instruments start useful rollout, feedback to with Now with for evaluate we in us will these a final versions as we the designed way release. of of that the actual the are system

also released of interest, with instruments adequate have tend to And sites picked be whole we that so new been And haven’t yet expressed have to familiar the to but choose sites we technologies those that that volume, and are market. from have and host new sites haven’t these yet. a

Destiny Buch

it. Got

commentary impact around Okay. Yes, impact definitely. top that problem How you I’m line OUS? think accreditation any And XXXX? in a your that’s in Europe. commercial to have, good strategy curious your might then about

Erik Holmlin

the it which bill say In qualifies adoption a increases it’s care that test. in or, regional United a and, organizations is way of to happening, a wouldn’t it’s therefore, first part but laboratory-developed strategy. line, that’s necessarily U.S., organized level unlike top process country organized accreditation which accreditation countries, the which top the But to to taking impacts can be for all, it’s region meets criteria be Well, to the level for the them is in responsibility certain at each – validation reimbursement. at not something it’s that I unique some States. of the the can laboratory comparable And in that line, of similar the overall systems it in their state-level quality is health

And to menu. increase so and the ability the a run them once it site assays then is accredited, the gives

consumables levels we each so it’s at time. drive per-site there to look expand higher menu grow compliance more and more an will have utilization. be region more necessary now assays, continue expectation that And that pull-through that to on over to at a that to and in more average basis assumes will, the which And the in the turn, the will from

have are we’re models taking place. revenues, and assume everyone have looking that reasonably there, at think taken seen our place, that that accreditations we’ve that I the out they So and we informing these

Destiny Buch

of? that you I Thank much then, taking questions. for Okay. Got scientific And at aware the you. term, conferences Thank lastly do be it. the you have for any should any guess, near we me. so In presentations

Erik Holmlin

you, always thank keep Yes. apprised. Destiny. We’ll everyone – We’ll

the scientific We calendar across to advance. active of tend of all course the an that we happen over the and in those have meetings year, major announce

keeping there. we you posted will be So

Destiny Buch

it. Got Thanks again.

Operator

you. Thank

next of question the Oppenheimer. from from Our comes DeGeeter Kevin line

line Your is open. now

Susan Chor

Susan This is Kevin. on Hi. for

questions Just of reimbursement. on a couple

can what on on have any applying is? you one, turnaround first idea CPT? comment on the you for The that category do process the X And

Erik Holmlin

So need the submission a at period. function process all and code involves of the application has process And And submitted is will committee, by – committee to part in assignment they reviewed that that look and evaluation would are given AMA a their that the provide. CPT the of the to be applications a different need Evidence for by States. code, the the evaluate labs, the mass codes mass LDTs critical utilization it, existence call is a of, that the and for critical laboratory-specific United have such in for of such developed that as applications PLA codes. based are on been different that a let’s

And so we seen know we’ve that.

code. that whether specific is it’s we there’s over any a to recommended unfolds connected in chance code be committee code approved, roughly determines the amount year. first for could a could that’s and of have the of reason, utilization, for event methodology. issue that’s evidence good half And to connected development the And the reapply. then outcomes so appropriate for to And And and process the code the of process be to pricing that happens denied, the The approved. that there’s would the a the

utilization, could be that we’ve market it’s beginning category we’re up we’re CPT for committee that the excited code, and need And adoption applications it. obviously potentially this we The X feel we submitting decide. are and that. reflect the reached at the to believe on that due, the in to favorably need And the but of level so we’ll of

Susan Chor

a that’s agree I really important milestone. No, Yes.

staying quarter? an know on the whether or not the do big next Just following was study a reimbursement, in steps you the pretty that guys I postnatal have deal on get topic the fourth reimbursement. are of you idea what

Erik Holmlin

Yes.

code. studies of coding a of and a are factor CPT can talked And and combination be think ways into I talking about say these as something which them. X we can be about would are I reimbursement. coverage. assay process – coded, variety in And a the we’ve described an of there reasonably category about so So reimbursement, And

key. Of determine their of and X the whether process a important to ones, in some coverage CPT the clerical, Coding coverage going they assay reimbursement. payers is it. for the where But again, general out and, a go come a critical of and or utilization. case, technology. And on mapping. made value utility Category warrants are particular and number the optical of or our or is code about decisions medical on by of is course, why heavily factors, massive that more societies rely In one that’s but itself we’re course, But respects, adoption enthusiastic through methodology assay is genome that’s workflow coverage

of demonstrations study endpoints. and evaluation in So the entail the that, of of all this utility as completion on so various of medical will greatly postnatal societies primary do the weigh our

looking diagnostic So impacts. a success for were primary why be time. looking on. release, those the if we’ll, in but the optical assay, interim far to at at And we’ve just used technical performance economic a yields, or mapping health endpoint genome turnaround rates so this critical workflow be next as entail in that’s us such then and reach like looked Overall overall study at key time, the diagnostic endpoints coverage year that over simplification decisions completion and and in will year of time, outcomes. health economic, completion of so diagnostic prominently will factor to be turnaround endpoints, over yields that’s patient coming into course But this and these will course,

Susan Chor

one Just question. last

are confident in maybe really are How exciting. foresee? you So Some of that lines? XXXX, you – time what time have study that risks several the lines about you these some of

Erik Holmlin

to cautious try about we careful be milestones. to these So and committing

generation, enrollment, enough strongly a them. go other to tend aspects enrollment. reporting, enrollment publication. put that analysis, staffing data we interpretation might to anybody that the we’ll shot reasonably believe us, conducting other around to COVID primarily at The there, have a data time confidence related able be can the and then be and But happen. If The like have is seeing them clinical we good get to we hit smoothly for process risk of and in any trial, the according to so that and closures And things it’s ultimately, a out we of line. risks we shortages face,

And we’re that’s have maybe anymore. lot And Omicron focused shortages seen, know through of these but ripple and sites talking are some are We’re behind activities, still and if where a companies staffing that, other but not about studies seeing feeling effects essential on us, of as the we closures take I backseat. don’t have a result, the occurred. of so a it, research surge activities, critical

probably But impact and staffing risk. data. generate analyze also So that’s to ability shortages biggest our the

to they So talked those. we these best to we’ve because that we societies it’s drive in them our manage coverage can of and are decisions the to play be about. have the of forward role and job the medical guidelines setting But mindful studies critical do that influencing

Susan Chor

quarter, the for on all that’s and us. Congratulations it. Got

Erik Holmlin

Yes. Thank you.

Operator

you. Thank

of Our Group. Jason McCarthy Maxim next question comes from from the line

great and for is Hey Your line congrats is Michael now open. guys. line on Q taking really the quarter. - Michael Thanks for Okunewitch a my Jason. questions This on Okunewitch

well, out two on Just line. revenue actually just – the start

more growth much of you of give income? terms rental bit that provide Saphyr bit by and you And versus placement utilization. of a organic of more how could was a increased could that If then how consumables terms if in granularity in unit driven much was

Chris Stewart

Yes.

October $X.X we of I did contribution mentioned of So QX. XXth. was a mention from first that was or BioDiscovery. acquisition million That The closed all, most there

So that was absent.

revenue. and QX, was balanced instruments and grew to organically both from QX across we about $X.X million, consumables So that

the Saphyr, OGM a was it that it in bit instrument towards equally QX. not like – was the – drove on of So growth. and almost if less And business well, it growth side yes, geared consumable was all most, little

Michael Okunewitch

direct what potential adoption assay All question perspective, from to be up a diagnostic study. right. revenue of a Thank primarily stream postnatal then a I’d From postnatal And get more Or regarding you. labs? the would on there driver assay? look like? to the among like the is this follow a commercial also Would a covered

Erik Holmlin

that It’s testing the really the former. in I mean, services broadly. business we’re I not think

choose sell selling multiple driving and it. a that research path. some proliferation but better to examples labs our we off next-generation lab that, know, companies in strategic working adoption software I mean we trying or business however off per around primarily of over us follow And we’re because for optical It genome we of mappers, But at And us. set disorder built applications revenues develop that probably products diagnostic We what multiple they the route, have on of by working space, as people so point the that’s and and clinical on to we run to genome their many proprietary and solution Illumina provider the time, and can’t taken have has want tests are whether a apply test. better to line their we the doesn’t to discovery analysis assays of in drive look to or But being the than technology. assays a community, we much that’s think neuro-developmental sequencing, we diagnostic pediatric they’re revenue that. in in that that enabling and high-value can ideas you believe are we for that’s

are genetic that’s the million completely disease. today. were name somebody XX% play out undiagnosed the initiative role strategic puzzling to our comes of Now genetic very know announce condition diseases, people cause, rare optical diseases questions know an mapping we disease in questions Rare rare is important answering genetic in you excited and some we genetic to There a recognition there is. genome of as genetic have but a as XX% in world may a those don’t so-called a whole. why when cause what a to disorders, the wrong may by it and there, or for XXX around to can applications yesterday diseases to as is sick impacted rare and are who be puzzling diseases

really RUGD this a solution study is areas genetic completing or diseases we position example rare optical undiagnosed postnatal genome it. so to field, call be the mapping an of as And will our go-to like where in

Michael Okunewitch

congrats quarter. you Thank All again on And much. very the right.

Erik Holmlin

Thank you.

Operator

turn call this At Thank am the to like I I would remarks. Erik showing back no further time, to you. questions. closing for over Holmlin

Erik Holmlin

for in want a to and questions. which you joining participating be around speaking good about I thank forward will we Gigi. everybody QX, to the the you, And to Thank look right Great. just again call corner.

So thank you very much.

Operator

concludes you participating. for This Thank today’s conference call.

disconnect. now may You

Bionano Genomics (BNGO) 2 Mar 222021 Q4 Earnings call transcript